A new systematic review and meta-analysis published in Frontiers in Psychiatry has found that people with dementia who take anticholinergic medicines (ACMs) or benzodiazepines (BZDs) face a higher risk of adverse clinical outcomes, including death. The pooled analysis of four studies involving 86,056 participants showed a 16% increase in the risk of all-cause mortality (hazard ratio 1.16, 95% confidence interval 1.07–1.26). However, the researchers rated the certainty of this evidence as very low under the GRADE framework, meaning the finding should be interpreted cautiously.
The review, conducted by researchers at Lund University in Sweden, examined 38 studies published between 2000 and 2026. Twenty of those studies focused on ACMs, 11 on BZDs, and seven on combined exposure. The studies included people formally diagnosed with dementia, comparing those who used these medications with those who did not or who had lower exposure.
Dementia affects an estimated 57 million people worldwide, a number projected to rise to 153 million by 2050. People living with dementia are especially vulnerable to medication-related harm due to frailty, multiple chronic conditions, and the use of several medications at once. ACMs — which include certain drugs for urinary incontinence, allergies, depression, and Parkinson's disease — and BZDs — used for anxiety, insomnia, and agitation — are both flagged as potentially inappropriate for older adults by prescribing guidelines such as the American Geriatrics Society Beers Criteria and the EU(7)-PIM list. Despite these recommendations, both classes continue to be prescribed in clinical practice.
The researchers found that the most consistently reported outcome across the studies was mortality. For other outcomes — including delirium, hospitalization, cognitive decline, and functional decline — the findings were more mixed, though they generally pointed toward potential harm. The review was not able to pool data for these outcomes due to differences in how studies defined and measured them.
The authors noted several limitations in the existing evidence. Many studies used different scales to measure anticholinergic burden, making comparisons difficult. Most were observational, meaning they can show an association but cannot prove that the medications caused the harm. The very low certainty rating for the mortality finding reflects concerns about study design, inconsistency, and potential confounding.
For university students studying medicine, pharmacy, or public health, the review highlights a real-world tension in geriatric prescribing: medications that can help manage symptoms may also carry serious risks for vulnerable populations. The findings reinforce current recommendations for cautious, individualized prescribing and regular medication reviews for people with dementia, and they underscore the need for deprescribing when clinically appropriate.
The review was registered in PROSPERO and followed PRISMA guidelines. The researchers called for future studies to use more standardized definitions of medication exposure, stronger causal-inference designs, and patient-centered outcomes such as quality of life.